TP53
2 stories
-
healthVenetoclax Combo Shows Strong Survival Gains in Older AML Patients
Phase II trial finds cladribine, low-dose cytarabine, and venetoclax alternating with azacitidine and venetoclax improves remission and survival in older AML patients.
-
healthCT Imaging Reveals Key Risk Factors for Fast-Growing Lung Cancer
New study identifies solid nodules, smoking, TP53 mutations, and family cancer history as critical predictors of aggressive lung cancer progression.